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Abstract The hush puppy mouse mutant has been shown
previously to have skull and outer, middle, and inner ear
defects, and an increase in hearing threshold. The ﬁbroblast
growth factor receptor 1 (Fgfr1) gene is located in the
region of chromosome 8 containing the mutation.
Sequencing of the gene in hush puppy heterozygotes
revealed a missense mutation in the kinase domain of the
protein (W691R). Homozygotes were found to die during
development, at approximately embryonic day 8.5, and
displayed a phenotype similar to null mutants. Reverse
transcription PCR indicated a decrease in Fgfr1 transcript
in heterozygotes and homozygotes. Generation of a con-
struct containing the mutation allowed the function of the
mutated receptor to be studied. Immunocytochemistry
showed that the mutant receptor protein was present at the
cell membrane, suggesting normal expression and traf-
ﬁcking. Measurements of changes in intracellular calcium
concentration showed that the mutated receptor could not
activate the IP3 pathway, in contrast to the wild-type
receptor, nor could it initiate activation of the Ras/MAP
kinase pathway. Thus, the hush puppy mutation in ﬁbro-
blast growth factor receptor 1 appears to cause a loss of
receptor function. The mutant protein appears to have a
dominant negative effect, which could be due to it dime-
rising with the wild-type protein and inhibiting its activity,
thus further reducing the levels of functional protein. A
dominant modiﬁer, Mhspy, which reduces the effect of the
hush puppy mutation on pinna and stapes development, has
been mapped to the distal end of chromosome 7 and may
show imprinting.
Introduction
Genetic defects play a major role in the causation of
hearing impairment in the human population and many
different genes can be involved. More than 130 loci have
been identiﬁed for nonsyndromic deafness alone, with
additional loci involved in syndromic deafness (for review
see Nance 2003; Van Camp and Smith (2011). Although it
is expected that many more novel genes are yet to be
identiﬁed, in many cases the role of those genes already
known to be associated with deafness are not fully under-
stood. Mouse models of deafness can be used to study the
effects of mutated genes, with the aim of correlating the
phenotypic consequences of the mouse mutations to human
conditions.
The hush puppy mutant (gene symbol Hspy) was iden-
tiﬁed in an N-ethyl-N-nitrosourea (ENU) screening pro-
gramme (Hrabe ´ de Angelis et al. 2000). The phenotype of
heterozygous mutant mice was described previously (Pau
et al. 2005). Hush puppy heterozygotes were found to have
Electronic supplementary material The online version of this
article (doi:10.1007/s00335-011-9324-8) contains supplementary
material, which is available to authorized users.
J. A. Calvert   M. Fleming   M. A. Lewis   K. P. Steel (&)
Wellcome Trust Sanger Institute, Wellcome Trust Genome
Campus, Hinxton, Cambridge CB10 1SA, UK
e-mail: kps@sanger.ac.uk
S. G. Dedos
Department of Pharmacology, University of Cambridge,
Cambridge, UK
K. Hawker
MRC Institute of Hearing Research, Nottingham, UK
Present Address:
S. G. Dedos
Department of Zoology and Marine Biology, Faculty of Biology,
National and Kapodistrian University of Athens, Athens, Greece
123
Mamm Genome (2011) 22:290–305
DOI 10.1007/s00335-011-9324-8defects in all regions of the ear. In the outer ear the pinna
was small, misshapen, and low-set on one or both sides. In
the middle ear the stapes were malformed in both ears and
incus abnormalities were also found in some cases. Pre-
liminary scanning electron microscopy studies of the inner
ear indicated that small regions of the organ of Corti had
two rows of outer hair cells instead of the usual three rows.
Hearing impairment varied between individual animals, but
compound action potential thresholds revealed that all
heterozygotes had some increase in thresholds compared to
littermate controls. In addition to the ear phenotype, the
skull and mandible were shorter in the anteroposterior axis.
There was a large amount of variation in the phenotype
between individual animals, indicating that there was not
full penetrance of the phenotype. For example, penetrance
for the pinna defect was estimated at 71%. Genetic map-
ping of the mutation isolated it to chromosome 8 between
markers D8Mit58 and D8Mit289.
The tyrosine kinase receptor ﬁbroblast growth factor
receptor 1 (Fgfr1) was a very good candidate gene within
the identiﬁed region because it is known to be expressed in
the inner ear, where it is required for development of the
auditory sensory epithelium (Pirvola et al. 2002). Stimu-
lation of Fgfr1 by ﬁbroblast growth factors (FGFs) leads to
dimerisation and autophosphorylation of the receptor into
its active form. The activated receptor interacts with sev-
eral pathways, including the Ras/MAP kinase pathway and
the PLCc/IP3 pathway (for review see Eswarakumar et al.
2005). Previous studies have shown that Fgfr1 is involved
in a wide variety of processes, including cell migration
during gastrulation (Deng et al. 1994; Yamaguchi et al.
1994), patterning of the anteroposterior axis (Hajihosseini
et al. 2004; Partanen et al. 1998), craniofacial morpho-
genesis (Lee et al. 2008; Riley et al. 2007; Rizzoti and
Lovell-Badge 2007), segmentation of the presomitic
mesoderm (Wahl et al. 2007), and development of sensory
organs (Hebert et al. 2003; Pirvola et al. 2002).
The current study has identiﬁed a single-point mutation
in the Fgfr1 gene in the hush puppy mutant. This mutation
leads to an amino acid substitution in the kinase domain of
the receptor. Study of the homozygote phenotype revealed
that the mutation is lethal at approximately embryonic day
(E) 8.5, conﬁrming the role of Fgfr1 in early development
(Hoch and Soriano 2006). Mutant protein is detected at the
cell membrane as normal, but functional studies showed
that the mutation causes loss of activation of the Ras/MAP
kinase and PLCc/IP3 pathways. The severity of the het-
erozygote phenotype implies that the mutant protein may
be exerting a dominant negative effect, possibly by dime-
rising with and inhibiting the activity of wild-type protein.
In addition, we found evidence of modiﬁers in the C57BL/6J
genome that ameliorate the effect of the Hspy mutation.
The effects have been analysed using a backcross panel,
and a dominant modiﬁer, Mhspy, has been localised to the
distal end of chromosome 7. Mhspy shows different effects
depending on whether it is inherited from the mother or the
father, consistent with imprinting.
Methods
Mutant mice
The founder mouse (carrying the hush puppy mutation;
DEA9) was generated in a large-scale N-ethyl-N-nitro-
sourea (ENU) mutagenesis programme (Hrabe ´ de Angelis
et al. 2000; Pau et al. 2005). The colony was maintained by
heterozygote 9 wild-type matings on a C3HeB/FeJ back-
ground, and heterozygote 9 heterozygote matings were
used to produce the homozygotes for analysis. Age-mat-
ched wild-type littermates were used as controls. Once the
gene was identiﬁed, DNA was extracted from each animal
and genotyped using PCR primers 1 and 2 (Table 1), which
introduced a DdeI restriction site into DNA that contained
the mutation. The PCR product was then digested with
DdeI (100 U/ml) overnight at 37C, and the resulting
fragments were viewed using ethidium bromide agarose
gel electrophoresis. Wild-type DNA gave a single band of
208 bp, heterozygote DNA showed as two bands at 184
and 208 bp, and homozygote mutant DNA gave one band
at 184 bp.
Sequencing
DNA was extracted from wild-type and heterozygous
animals. Primers were designed with the aid of Primer3
(Rozen and Skaletsky 2000) to amplify each exon of Fgfr1.
PCR conditions were as follows: denaturation at 94C for
5 min; 35 cycles of denaturation at 94C, followed by
annealing at 58C and extension at 72C for 30 s each;
ﬁnal extension at 72C for 5 min. PCR products were then
sequenced and the resulting sequences were examined
using GAP4 software (Bonﬁeld et al. 1995).
RT-PCR
Whole embryos, including the yolk sac, were dissected at
E8.5 and snap-frozen in liquid nitrogen. Total RNA was
isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA,
USA). The RNA was treated with DNase I (Sigma, UK)
to remove any DNA contamination. Half of the puriﬁed
RNA was reverse-transcribed to cDNA using SuperScript
II-reverse transcriptase (Invitrogen, Carlsbad, CA, USA),
and the remainder of the RNA was used as a negative
control. PCR reactions were carried out with 0.5 llo f
cDNA and a ﬁnal concentration of 500 nM of each primer.
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above, with the exceptions that the annealing temperature
was 57C and only 30 cycles were used. The primers for
Fgfr1 (Table 1, primers 3 and 4) were designed to
encompass the mutation in order to genotype embryos by
sequencing the ampliﬁed products (as described above).
Primers for b-actin (Table 1, primers 5 and 6) were used as
an internal control. To quantify the relative change in
transcript level between genotypes, band intensities were
measured using ImageJ (http://rsb.info.nih.gov/ij/index.
html). Background levels of luminescence were sub-
tracted from mean band intensities, and Fgfr1 transcript
level was normalised to b-actin transcript.
Clone mutagenesis
The full-length cDNA of murine Fgfr1 in pBlueScript was
obtained from ATCC [Manassas, VA, USA; pBSmFGFR(L),
clone number 63344 (Jin et al. 1994)]. The open reading
frame of mFgfr1 was ampliﬁed by PCR from the full-length
cDNA using Pfx DNA polymerase (Invitrogen) and primers
7 and 8 (Table 1). After digestion with SalI-EcoRI, the PCR
product was ligated into pENTR1a (Invitrogen) to generate
vector pENTR1a-mFgfr1. Comparison of the predicted
amino acid sequence to that of Fgfr1 from wild-type mice
with the same genetic background as hush puppy (C3HeB/
FeJ) revealed three amino acid differences caused by single
nucleotide changes: E265 ? K, P457 ? L, S763 ? N.
These differences were corrected in vector pENTR1a-
mFgfr1 using a QuikChange multisite-directed mutagen-
esis kit (Stratagene, Agilent Technologies, Santa Clara, CA,
USA) and primers 9, 10, and 11, to create vector Fgfr1
WT.In
this vector, a ﬂag-tag epitope (DYKDDDDK) was inserted
afterthe signalpeptideofmFgfr1 (between aminoacidsT20
and A21) by site-directed mutagenesis using a Quik-
Change II XL site-directed mutagenesis kit (Stratagene)
and primers 12 and 13 to generate vector Fgfr1
WT-ﬂag. The
hush puppy mutation W691 ? R was added to Fgfr1
WT-ﬂag
withtheQuikChangeIIXLsite-directedmutagenesiskitand
primers 14 and 15 to generate vector Fgfr1
Hspy-ﬂag. Vectors
Fgfr1
WT, Fgfr1
WT-ﬂag, and Fgfr1
Hspy-ﬂag were recombined
into the expression vector pcDNA3.2 using Gateway LR
Clonase Enzyme Mix (Invitrogen).
Cell culture and transfection
HEK293 cells were chosen for transient expression studies
due to their lack of endogenous Fgfr expression but intact
MAP kinase pathway (Li et al. 2004). Cells were main-
tained in culture with D-MEM:F-12 media supplemented
with foetal bovine serum (10%), glutamine (292 lg/ml),
penicillin (100 U/ml), and streptomycin (100 lg/ml). Cells
were plated into 6- or 24-well plates as required and
allowed to adhere for at least 24 h. Transient transfections
were performed using Lipofectamine 2000 (Invitrogen).
Immunocytochemistry
HEK293 cells were plated onto 13-mm coverslips coated
with poly-L-lysine (0.01%) and were transfected with
0.5 lg of vector DNA per coverslip as described above.
Approximately 24 h after transfection, cells were washed
twice with Tris-buffered saline (TBS: 10 mM Trizma base,
Table 1 Primer sequences for genotyping (1 and 2), RT-PCR (3–6), and clone mutagenesis (7–15)
Primer Function Direction Sequence (50–30)
1 Genotyping Forward GTGGTCTTTTGGAGTGCTCCTG
2 Genotyping Reverse GCTTGCCAGTGGTGGATCCAA
3 Fgfr1 Forward CCGGATCTACACACACCAGA
4 Fgfr1 Reverse CCACCAACTGCTTGAACGTA
5 b-actin Forward ATCCATGAAACTACATTCAATTCCAT
6 b-actin Reverse ACCGATCCACACAGAGTACTTGCGC
7 ORF Forward GATCAGTCGACGCCACCATGTGGGGCTGGAAGTGCCTCCTC
8 ORF Reverse GATCAGAATTCTCAGCGCCGTTTGAGTCCACTGTTGGCAAGCTGGGT
9 E265 K Forward CAGGGCTGCCTGCCAACAAGACAGTGGCCCTGGGC
10 P457L Forward CAGCGGGACCCCCATGCTGGCTGGAGTCTCCGAATATG
11 S763 N Forward CATTGTGGCCTTGACCTCCAACCAGGAGTATCTGGACCTG
12 Flag tag Forward AGGTTGGGGCTGGCCTGGCCTTATCGTCATCGTCTTTGTAGTCAGTGCAGAGAGTGGCTGTG
13 Flag tag Reverse CACAGCCACTCTCTGCACTGACTACAAAGACGATGACGATAAGGCCAGGCCAGCCCCAACCT
14 Hspy Forward GGTCTTTTGGAGTGCTCTTGAGGGAGATCTTCACTCTGGG
15 Hspy Reverse CCCAGAGTGAAGATCTCCCTCAAGAGCACTCCAAAAGACC
ORF open reading frame
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123150 mM NaCl, pH 7.4) and ﬁxed in methanol and acetone
(1:1) for 1 min. Coverslips were washed three times with
TBS. Anti-ﬂag antibody conjugated to FITC (10 lg/ml;
Sigma) was applied to each coverslip for 1 h at room
temperature. Coverslips were washed three times with TBS
before being mounted onto glass slides. Cells were then
examined under a ﬂuorescence microscope at 488 nm and
pictures were taken using AxioVision (release 4.3)
software.
Single-cell calcium imaging
Single-cell calcium imaging (Tovey et al. 2003) was per-
formed on transiently transfected cells to determine if the
mutated Fgfr1 receptor could activate the IP3 signalling
pathway. HEK293 cells were plated onto 22-mm coverslips
and transfected with the appropriate vector DNA. Twenty-
four hours post transfection, cells were loaded with 2 lM
fura-2/AM for 1 h at room temperature. Coverslips were
washed in HBS (135 mM NaCl, 5.9 mM KCl, 1.2 mM
MgCl2, 1.5 mM CaCl2, 11.6 mM HEPES, 11.5 mM glu-
cose, pH 7.2) for 30 min at room temperature and were
then imaged. Cells were excited alternately at 340 and
380 nm for 500 ms each using a monochromator (Cairn,
UK). Emitted ﬂuorescence was collected at 510 nm, and
images were recorded using a MicroMax 1300Y/HS CCD
camera (Princeton Instruments UK, Buckinghamshire,
UK). Data was collected and analysed using Metaﬂuor
software (Molecular Devices, Sunnyvale, CA, USA). Cells
were stimulated with 100 ng/ml FGF1 with 5 lg/ml hep-
arin for 5 min, with data sampled every 5 s. To ensure that
cells selected were capable of responding, they were then
exposed to 1 mM carbachol (CCh) for 2 min. Fifty cells
were selected from each experiment for analysis, and any
that failed to respond to CCh were discarded. Each
experiment was performed on two independent transfec-
tions. Traces were corrected for baseline [Ca
2?]i, and the
ﬂuorescence ratios (F340/F380) for individual cells were
calculated. These ratios were then calibrated to [Ca
2?]i by
referencing a lookup table created using standard Ca
2?
solutions (Molecular Probes Calcium Calibration Kit with
1 mM MgCl2), using the following equation (Grynkiewicz
et al. 1985):
Ca2þ 
i¼ Kd:QR   Rmin ðÞ = Rmax   R ðÞ ½ 
where Kd is the dissociation constant for fura-2 binding to
Ca
2? (140 nM); R is the ﬂuorescence ratio (F340/F380)a t
any given experimental time point; Rmin is the minimum
ﬂuorescence ratio determined in Ca
2?-free media (10 mM
EGTA); Rmax is the maximum ﬂuorescence ratio deter-
mined in the presence of saturating [Ca
2?]( * 37 lM free
Ca
2?); and Q is Fmax/Fmin at 380 nm.
Cell stimulation and Western blotting
To determine whether the mutant receptor could activate
the Ras/MAP kinase pathway, cells were stimulated with
agonist and then lysed. Western blotting was then per-
formed on cell lysates to look for phosphorylation of MAP
kinase (MAPK) as an indication of activation of the path-
way. HEK293 cells were plated onto 6-well plates and
transfected with 1 lg of the required vector DNA per well.
Twenty-four hours after transfection, the medium was
removed and cells were placed in serum-free medium for
4 h. Cells were washed with HBS before stimulation.
Stimulated cells were exposed to 100 ng/ml FGF1 and
5 lg/ml heparin in HBS for 10 min at 37C. Unstimulated
cells had HBS applied during this time. Cells were washed
with cold HBS and lysed in 1 ml of 1 9 IP buffer (from a
protein G immunoprecipitation kit, Sigma). Lysates were
incubated on ice for 15–20 min before being centrifuged.
The supernatant was removed and stored at –80C with
10% glycerol until required.
SDS-PAGE was performed using 7.5% acrylamide gels.
Proteins were transferred onto nitrocellulose membranes
using a mini trans-blotter (Bio-Rad Laboratories, Hercules,
CA, USA). Membranes were incubated in blocking solu-
tion (10% skimmed milk in TTBS: 50 mM Trizma base,
150 mM NaCl, 0.1% Tween 20, pH 8) for 1–2 h before
overnight incubation with the primary antibody at 4C.
Membranes were washed in TTBS before application of
secondary antibody (anti-rabbit IgG HRP conjugate,
0.1 lg/ml). After washing with TTBS, membranes were
developed using ECL plus Western blotting detection
reagent (Amersham, UK) for 5 min. ECL hyperﬁlm
(Amersham) was used to visualise the bands.
In some cases there were low levels of background
phosphorylation of MAPK. To compensate for this, levels
of phosphorylated MAPK were expressed as a ratio against
total MAPK in each lysate, using ImageJ to measure band
intensity, as described above.
Antibodies
For immunocytochemistry, anti-ﬂag M2 monoclonal FITC-
conjugated antibodies were obtained from Sigma. Anti-p44/
42 MAP kinase and anti-phospho-p44/42 MAP kinase
antibodies for Western blotting were acquired from Cell
SignalingTechnology(Danvers,MA,USA).Theanti-rabbit
IgG HRP secondary antibodies for Western blotting were
from Upstate Biotechnologies (Lake Placid, NY, USA).
Mapping the modiﬁers
Mice heterozygous for the hush puppy mutation were
outcrossed to C57BL/6J. The resulting F1 offspring were
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tion were crossed to C3HeB/FeJ to produce the backcross
mice used for mapping (n = 379 backcross mice). Hush
puppy heterozygotes from the backcross generation
(n = 172) were collected between 5 and 8 weeks of age
and used for analysis of the stapes phenotype, skull length,
and pinna size except the ones excluded as listed below. An
additional 26 heterozygous backcross animals were col-
lected between 7.5 and 8 months of age. These animals
were not used in the linkage analysis for the pinna and skull
because these tissues continue to grow beyond 8 weeks of
age. DNA was prepared from all backcross mice and used
for a genome scan using a panel of polymorphic dinucle-
otide repeat markers covering all 19 autosomes (Table 2).
There was no evidence from the distribution of phenotypes
for any X-linked modiﬁer.
Pinnae were removed from each mouse (n = 172)
shortly after the mouse was culled. Five mice were not
included because of pinna damage. Pinnae were ﬂattened
under a microscope slide and photographed at a constant
magniﬁcation. Each pinna was outlined by hand in Adobe
Photoshop and the surface area was measured using
ImageJ.
After removal of the pinnae, heads were skinned and then
placed in 10% neutral buffered formalin for storage prior to
dissection of the ossicles. Twenty-seven of the 172 back-
crossmicehadoneorbothstapeseitherlostorbrokenduring
dissection and could not be used for analysis. An additional
26 backcross mice were collected at 7.5–8 months and
processed in the same manner. Stapes were given a score
according to how badly affected they were.
Following dissection of the ossicles, the skulls were
ﬁxed in ethanol, macerated with potassium hydroxide,
stained with Alcian Blue and Alizarin Red, and cleared in
glycerol using a standard protocol (Inouye 1976; McLeod
1980).Each skull (n = 172) was photographed with a scale.
ImageJ was used to measure the length of the skull between
the end of the nasal bone and the caudal edge of the
interparietal bone. The width of the skull was also mea-
sured along the suture at the back of the parietal bone. Nose
angle was measured by deviation from the midline of the
skull, starting at the base of the nasal bone.
Table 2 Markers used for the genome scan
Marker Position (cM) Marker Position (cM) Marker Position (cM)
D1Mit429 8.4 D6Mit254 60.55 D13Mit3 8.96
D1Mit415 53.06 D7Mit178 0.5 D13Mit88 21
D1Mit353 90.34 D7Mit230 22.45 D13Mit9 32.44
D2Mit369 27.3 D7Mit66 57.5 D14Mit99 1.51
D2Mit237 28 D7Mit105 63.5 D14Mit260 21.21
D2Mit107 75.6 D7Mit259 72 D14Mit225 44.1
D2Mit200 98.36 D8Mit339 23 D14Mit266 60
D3Mit117 2.35 D8Mit113 52 D15Mit175 5.72
D3Mit339 29.25 D8Mit321 59 D15Mit43 58.01
D3Mit199 56.1 D8Mit280 72 D16Mit165 11.17
D3Mit258 70.3 D9Mit224 17 D16Mit63 30.76
D3Mit19 87.6 D9Mit162 30 D16Mit189 55.2
D4Mit111 21.9 D9Mit214 58.79 D16Mit86 66
D4Mit111 21.9 D10Mit206 4.47 D16Mit106 71
D4Mit58 40.62 D10Mit3 23 D17Mit238 2.22
D4Mit354 71 D10Mit194 29 D17Mit126 21.8
D4Mit234 71 D10Mit180 65.22 D17Mit155 50.71
D4Mit42 81 D11Mit71 0 D18Mit64 2
D5Mit345 1 D11Mit140 25.73 D18Mit37 21
D5Mit391 18.03 D11Mit35 44.74 D18Mit50 41
D5Mit115 40.01 D11Mit99 63.21 D19Mit59 0.5
D5Mit292 80 D12Mit240 3 D19Mit19 26
D6Mit138 2.35 D12Mit69 23.88 D19Mit137 55.7
D6Mit268 15.6 D12Mit14 37
D6Mit323 36.5 D12Nds2 59
Positions are given in cM (MGI). All markers were used for each scan, with the exception of D8Mit321, which was used only for the scan using
stapes sums of 2 or 3 (Fig. 7a)
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Statistical tests were performed using an unpaired two-
tailed t test, with P\0.05 considered signiﬁcant. A
regression analysis was carried out to compare stapes score
versus pinna size; P\0.05 was considered signiﬁcant.
Normality, linearity, and homoscedasticity were tested to
ensure accuracy of the regression. The Shapiro-Wilks test
was used to assess the normality of the distributions of the
sums of the stapes scores of mice carrying C57BL/6J DNA
from the father and from the mother.
Results
Hush puppy mutants carry a mutation in the Fgfr1 gene
DNA was extracted from three wild-type and four hetero-
zygous animals. Primers were designed to amplify each
exon of Fgfr1. Analysis of the sequence revealed a single-
point mutation, T2128A, in exon 15 that was consistently
found in all heterozygotes examined (Fig. 1a). This
nucleotide change leads to a substitution in the amino acid
sequence such that the tryptophan residue at position 691 is
replaced by arginine (W691R). This missense mutation
occurs in a region of the Fgfr1 protein that is highly con-
served across species orthologues, and also across the
family of Fgfrs (Fig. 1b).
Homozygous hush puppy mutants die at approximately
E8.5
Once the mutated gene had been identiﬁed, it was possible
to study the effects of the mutation on the protein. Previous
studies have shown that overexpression of Fgfr1 leads to
anteroposterior patterning defects such as additional digits
(Hajihosseini et al. 2004). Conversely, Fgfr1-null mice die
early in gastrulation, at approximately E8.5 (Deng et al.
1994; Yamaguchi et al. 1994). The homozygote hush
puppy phenotype was examined to determine if any of the
previously reported phenotypes could be identiﬁed. No
homozygous animals were present from 56 live births from
heterozygote 9 heterozygote matings, indicating that the
embryos died during gestation. Embryos were examined at
a range of ages to determine at what stage homozygotes
died. No live homozygous animals were detected at E18.5
(0/15), E14.5 (0/18), or E10.5 (0/18), although three
homozygous embryos in the process of resorption were
found at E10.5. At E8.5 homozygous embryos were
detected by sequence analysis, and they were distinguished
from littermates by being developmentally retarded, with a
restriction at the embryonic/extra-embryonic boundary
(Fig. 1c). In E7.5 embryos the restriction was evident in
most cases, although in some it was not as obvious. This
phenotype was the same as previously reported in Fgfr1-
knockout mice (Deng et al. 1994; Yamaguchi et al. 1994),
supporting the suggestion that the W691R mutation in
Fgfr1 is responsible for the phenotype in hush puppy
mice.
Fig. 1 The hush puppy phenotype is caused by a mutation in Fgfr1.
a Fgfr1 sequence showing the point mutation T2128A (arrow),
located in exon 15 of the gene. Sequences from wild-type animals
(top), heterozygotes (middle), and homozygotes (bottom) are shown.
b The point mutation causes the missense mutation W691R in a
highly conserved tyrosine kinase motif, subdomain IX (complete
domain shown). Numbers shown are the residue number for the
equivalent amino acid in each sequence. c Development of homo-
zygous embryos is arrested at *E8.5. Mutant embryos (E8.5) show a
characteristic restriction at the embryonic/extra-embryonic boundary
(arrow). Heterozygous embryos have no phenotype at this stage. Scale
bar = 250 lm. h human, r rat, m mouse, x Xenopus, z zebraﬁsh,
n Eastern newt, d Drosophila, ys yolk sac, hf head fold, s somites,
A anterior, P posterior
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The next question was whether the gene was transcribed
properly. Messenger RNA was extracted from embryos at
E7.5, the stage at which mutants were found to still be
viable but were generally identiﬁable due to their pheno-
type. It was found that cDNA was present for animals both
heterozygous and homozygous for the mutation (Fig. 2a).
b-actin was used as an internal control to compare levels of
expression between samples. The transcript level of Fgfr1
was normalised relative to b-actin within each genotype
group (Fig. 2b). The relative cDNA levels of Fgfr1 were as
follows: wild-type, 1.15 ± 0.2 (n = 3 animals); heterozy-
gote, 0.49 ± 0.1 (n = 7 animals); and homozygotes,
0.23 ± 0.1 (n = 8 animals). There was a signiﬁcant
reduction in Fgfr1 transcript levels compared to wild-type
in both heterozygotes (42.6% of wild-type levels,
P\0.05) and homozygotes (20% of wild-type levels,
P\0.001). It has been shown that hypomorphs with
reduced transcript levels of only 10% of normal levels die
neonatally (Partanen et al. 1998; Pirvola et al. 2002),
suggesting that the reduction in transcript levels in hush
puppy homozygotes is unlikely to be sufﬁcient to cause
death at an early stage (i.e., E8.5), although different
genetic backgrounds of the hypomorphs and the hush
puppy homozygotes could inﬂuence the time of death.
Construct generation
In order to study the mutation in Fgfr1 further, a construct
of the mutated receptor was generated. Three clones were
created for study: a clone matching the sequence of Fgfr1
DNA from wild-type C3HeB/FeJ animals, Fgfr1
WT; the
wild-type clone with a ﬂag tag, Fgfr1
WT-ﬂag; and the ﬂag-
tagged clone with the hush puppy mutation, Fgfr1
Hspy-ﬂag.
These constructs were transiently expressed in human
embryonic kidney (HEK293) cells for further study of the
function of the mutated receptor.
Fgfr1
Hspy protein is localised at the cell membrane
To analyse whether Fgfr1
Hspy was localised normally, the
expression pattern was examined by immunocytochemis-
try. It was possible that if the mutation caused a disruption
in the tertiary structure of the protein, it may not be
expressed at the cell membrane due to processing or traf-
ﬁcking errors. HEK293 cells were transiently transfected
with either Fgfr1
WT-ﬂag or Fgfr1
Hspy-ﬂag. Immunocyto-
chemistry using an anti-ﬂag FITC-conjugated antibody
demonstrated that both the wild-type and the mutated
receptor were expressed at the cell membrane (n = 3
experiments; Fig. 3). This indicates that the mutation in
Fgfr1 does not prevent translation of the protein and also
does not affect the trafﬁcking of the receptor to the mem-
brane. This in turn indicates that the effect of the mutation
is likely to be a functional one.
The mutation prevents mobilisation of intracellular
calcium
Activated Fgfr1 interacts with the phospholipase Cc
(PLCc) pathway, leading to production of IP3, which in
turn causes an increase in intracellular calcium ion con-
centration ([Ca
2?]i). Changes in [Ca
2?]i were examined in
response to stimulation with FGF1 and heparin (heparin is
an accessory molecule that facilitates Fgf binding to Fgfrs)
(Kan et al. 1993; Nance 2003; Rapraeger et al. 1991). A
subsequent application of CCh (1 mM) was used to ensure
cell viability. CCh is an agonist of muscarinic
Fig. 2 Reverse transcription PCR of mRNA (E7.5) from each
genotype. The results show that the mutation caused a reduction in
the amount of transcript present. a PCR products for wild-type (?/?,
n = 3 animals), heterozygote (Hspy/?, n = 7 animals), and homo-
zygote (Hspy/Hspy, n = 8 animals) are shown for both Fgfr1 and b-
actin, the internal control. Control used water in place of cDNA to
check for contamination. bp, base pairs. b Levels of Fgfr1 transcript
per genotype, normalised to b-actin transcript. Fgfr1 transcript is
signiﬁcantly reduced compared to wild-type in heterozygotes
(P\0.05) and homozygotes (P\0.001)
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123acetylcholine receptors (mAchR), which are endogenously
expressed in HEK293 cells. Cells that did not have a CCh
response were discounted as it was assumed they lacked a
functional Ca
2? store or were unhealthy. Nontransfected
cells did not respond to FGF1, conﬁrming that there was no
endogenous expression of Fgfr1 in the cells (n = 194 cells;
Fig. 4a, Table 3). Cells expressing either Fgfr1
WT or
Fgfr1
WT-ﬂag showed an increase in [Ca
2?]i on application of
FGF1 and heparin. There was no difference in the number
of cells that responded to FGF1 application between cells
expressing Fgfr1
WT (90/194) and Fgfr1
WT-ﬂag (90/189;
Table 3). However, there was a small reduction in the
amplitude of the response to FGF1 in cells expressing
Fgfr1
WT-ﬂag compared to Fgfr1
WT (134 ± 8.9 and
177.5 ± 12 nM, respectively; Table 3, Fig. 4b, c). This
could be due to lower levels of expression of the construct
within cells, or a slightly reduced ability to respond to
agonist caused by the presence of the ﬂag tag. Because the
introduction of the ﬂag tag did not cause large changes,
Fgfr1
Hspy-ﬂag was examined for functional activity. Cells
expressing Fgfr1
Hspy-ﬂag showed no rise in [Ca
2?]i when
stimulated with FGF1 and heparin (0/376; Table 3,
Fig. 4d). The same cells all responded to CCh (1 mM),
conﬁrming that lack of response to FGF1 was not due to
cell death. In cells expressing Fgfr1
WT or Fgfr1
WT-ﬂag, the
responses to CCh were of signiﬁcantly reduced amplitude
compared to the responses in nontransfected or Fgfr1
Hspy-
ﬂag-expressing cells. This is most likely due to the cells
being unable to reﬁll their intracellular Ca
2? stores sufﬁ-
ciently between agonist applications, resulting in a smaller
response to the second agonist, i.e., CCh. The mean
transfection efﬁciency of the Fgfr1
WT and Fgfr1
WT-ﬂag cells
was 47%, and a similar transfection efﬁciency might be
expected with Fgfr1
Hspy-ﬂag. Counts of transfected cells in
immunocytochemistry experiments showed that there were
equal levels of transfection between Fgfr1
WT-ﬂag and
Fgfr1
Hspy-ﬂag constructs (data not shown). In the Ca
2?
imaging experiments, of the 376 cells tested with
FGF1, * 177 would be expected to be expressing
Fgfr1
Hspy-ﬂag. The lack of response in any cells demon-
strated that Fgfr1
Hspy-ﬂag was unable to stimulate the
release of intracellular Ca
2?. This could be due to an
inability to activate the PLCc pathway, which may occur if
the receptor’s ability to phosphorylate was impaired.
The MAP kinase pathway is not activated
by Fgfr1
Hspy-ﬂag
Another pathway with which activated Fgfr1 interacts is
the MAPK pathway, leading to phosphorylation of MAPK
proteins. In order to determine whether the mutated
receptor could interact with this pathway, levels of phos-
phorylated MAPK (phospho-MAPK) under both normal
unstimulated and FGF-stimulated conditions were exam-
ined by Western blotting (n = 5 lysates; Fig. 5). To com-
pensate for low levels of phospho-MAPK in nontransfected
cells, total MAPK was measured in each lysate and phos-
pho-MAPK was then normalised to MAPK levels. It was
found that there was a signiﬁcant difference in levels of
phospho-MAPK in nontransfected cells and cells express-
ing Fgfr1
WT-ﬂag (0.58 ± 0.23 and 2.17 ± 0.48, respec-
tively). The amount of phosphorylation in Fgfr1
Hspy-ﬂag-
expressing cells was not signiﬁcantly different than that of
nontransfected cells (0.70 ± 0.32). This indicates that the
mutated receptor is not capable of activating the MAPK
pathway, which could be expected if the mutated receptor
had lost its ability to phosphorylate.
Mapping a hush puppy modiﬁer, Mhspy
We observed that the hush puppy phenotype is greatly
reduced when crossed to a C57BL/6J background, sug-
gesting that there may be modiﬁers of Fgf signalling in the
C57BL/6J genome (Table 4). Accordingly, hush puppy
mice were outcrossed to C57BL/6J, then offspring from
that cross carrying the Hspy mutation were backcrossed to
C3HeB/FeJ. The heterozygote offspring from the back-
cross were examined for stapes defects, pinna size, and
skull size. A range of phenotypes was found for the fea-
tures examined (See Supplementary Figs.) so we analysed
mice at the two extremes for each measure. Linkage
analysis was carried out comparing those mice with the
Fig. 3 Fgfr1
Hspy-ﬂag is expressed at the cell membrane. Immunocytochemistry using an anti-ﬂag FITC-conjugated antibody showed that the
protein is localised to the cell membrane in cells expressing either Fgfr1
WT-ﬂag or Fgfr1
Hspy-ﬂag (n = 3 experiments). Scale bar = 20 lm
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with the most affected phenotype (the least modiﬁed).
There was no evidence from the distribution of phenotypes
for any X-linked modiﬁer (data not shown).
Stapes were given a score from 1 to 8, depending on
their appearance (Fig. 6, Supplementary Fig. 1) Mice used
for linkage analysis were those with a score of 3 or less for
left and right ears combined (Fig. 7a), and mice with a
combined score of 10 or more (Fig. 7b). Only animals with
scores available for both ears were used. A notable increase
in heterozygosity to over 80% was observed at the distal
end of chromosome 7 (markers D7Mit66, D7Mit105, and
D7Mit259) in the most modiﬁed animals. Conversely, a
decrease in heterozygosity was observed in the same
location in the least modiﬁed animals. The low level of
heterozygosity on proximal chromosome 8 corresponds
with the location of the Fgfr1 gene, which was selected for
carrying the C3HeB/FeJ-derived Hspy mutation.
Pinna size was measured at two ages: 5–8 weeks and
7.5–8 months (Supplementary Figs. 2 and 3). The animals
used for linkage analysis were those with a combined
Fig. 4 Changes in [Ca
2?]i in response to FGF1. Example traces are
shown of changes in [Ca
2?]i when FGF1 (100 ng/ml) with heparin
(5 mg/ml) is applied to the cells, followed by application of CCh
(1 mM, to ensure functional Ca
2? stores are present in the cells).
a There is no response to FGF1 in nontransfected cells (n = 194
cells). b Cells expressing Fgfr1
WT give a transient increase in [Ca
2?]i
on application of FGF1 (n = 194 cells). c Addition of the ﬂag tag to
the receptor (Fgfr1
WT-ﬂag) causes a small reduction in the amplitude of
the FGF1 response (n = 189 cells). d Cells expressing Fgfr1
Hspy-ﬂag
gave no increase in [Ca
2?]i in response to FGF1 (n = 376 cells)
Table 3 Percent and amplitude of [Ca
2?]i responses in cells expressing Fgfr1 constructs
No. of cells FGF1 (100 ng/ml) ? heparin (5 lg/ml) Carbachol (1 mM)
% responding Change in [Ca
2?]i (nM) % responding Change in [Ca
2?]i (nM)
Nontransfected 194 0 0 ± 0 100 604 ± 25
Fgfr1
WT 194 46.4 178 ± 12
a 100 78 ± 7
a,b
Fgfr1
WT-ﬂag 189 47.6 134 ± 9
a 100 97 ± 11
a,b
Fgfr1
Hspy-ﬂag 376 0 0 ± 0 100 561 ± 21
a There was a signiﬁcant difference in amplitude of [Ca
2?]i change between Fgfr1
WT and Fgfr1
WT-ﬂag in response to FGF1 with heparin, but there
was no difference between the CCh responses in these cells. CCh amplitudes are given for only the cells that responded to FGF1
b The response to CCh in cells that gave an FGF1 response was signiﬁcantly less than in cells that did not respond to FGF1
Fig. 5 The hush puppy mutation prevents phosphorylation of MAP
kinase. Cells were stimulated with 100 ng/ml FGF1 and 5 mg/ml
heparin and then examined for MAPK expression and phosphoryla-
tion via Western blotting (n = 5 lysates). The top blot shows total
MAP kinase in the cell lysates. The bottom blot indicates the amount
of MAP kinase that is phosphorylated when stimulated. There was no
signiﬁcant difference between cells expressing Fgfr1
Hspy-ﬂag and
nontransfected cells. ?, stimulated cells; -, unstimulated cells
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123surface area of both pinnae of 80 units or more (the most
modiﬁed; Supplementary Fig. 4A) and those with a com-
bined surface area of 60 units or less (the least modiﬁed;
Supplementary Fig. 4B) from the younger age group. As
for the stapes abnormalities, an increase of heterozygosity
in the most modiﬁed animals and a decrease of heterozy-
gosity in the least modiﬁed animals was observed at the
distal end of chromosome 7.
To determine if the pinna and stapes defects correlated, a
regression analysis was carried out, treating left and right
sides separately to ensure independence. A signiﬁcant neg-
ative correlation was observed for both sides (Supplemen-
taryFig. 5;leftear:r = -0.665,n = 181,P\2.2 9 10
-16;
right ear: r = -0.617, n = 182, P\2.2 9 10
-16).
Distal chromosome 7 is subject to imprinting, so we
asked whether the putative C57BL/6J-derived modiﬁer
might be among the imprinted loci by looking for any skew
in the degree of modiﬁcation of the stapes or pinna phe-
notype associated with inheriting the modiﬁer from the
mother or from the father. We replotted the numbers of
mice in each category for the stapes defect and for pinna
size according to whether the most distal chromosome 7
marker (D7Mit259) from the C57BL/6J parent was inher-
ited from the maternal or the paternal line. For the pinna
size, there was no evidence of any difference in distribution
(data not shown). However, for the stapes defect, there was
a marked skew in the distribution toward the more modi-
ﬁed (least abnormal) end of the distribution when the
C57BL/6J marker was inherited from the paternal line, but
there was no skew when it was inherited from the mother
(Fig. 8). This skew suggests that there may be imprinting
of the modiﬁer. For example, the allele derived from the
maternal line might be inactivated by imprinting while the
allele derived from the paternal line may show no
imprinting and hence may be active in compensating in
some way for the Hspy mutation.
The ratio of the skull length (nasal bone to interparietal
bone) to the skull width (measured along the suture of the
parietal bone) was used to determine which animals had
been most modiﬁed (length:width ratio [2.08) and least
modiﬁed (length:width ratio\2) (Supplementary Fig. 6A,
B). DNA from these animals was used for linkage analysis
(Supplementary Figs. 7 and 8). In addition, a small pro-
portion of mice had a marked bend in their nose (measured
by deviation from the midline of the skull starting at the
base of the nasal bone), and linkage analysis was carried
out on those with a bend of greater than 10 (deemed least
modiﬁed) and those with a bend of less than 2 (most
modiﬁed; Supplementary Figs. 6C, D and 9). However,
there were no obvious peaks in the genome scans for skull
length:width ratio or degree of nasal bend.
Discussion
In this study we have detected a missense mutation in the
tyrosine kinase domain of Fgfr1 leading to a tryptophan-to-
arginine substitution in the hush puppy mouse mutant.
Embryos that were homozygous for the Fgfr1
Hspy mutation
died at gastrulation and demonstrated the same character-
istics as Fgfr1-knockout embryos (Deng et al. 1994) in that
they die at the same time point, with a restriction at the
embryonic/extra-embryonic boundary. The mutated gene
was transcribed, although at a lower level than in the wild
type, and the protein was correctly processed and trafﬁcked
to the cell plasma membrane. The functional effect of the
mutation on the receptor was such that the receptor could
not activate at least two of its downstream pathways, the
Ras/MAP kinase pathway and the PLCc/IP3 pathway. In
effect, the mutation caused a loss of function of the
receptor. There are several possible explanations of why
Fgfr1, with the hush puppy mutation, may not be capable
Table 4 Correlation of Hspy genotype with ossicle and pinna defects in mice on their original C3HeB/FeJ genetic background and in F1 mice
from the outcross of Hspy/? mice on a C3HeB/FeJ background to C57BL/6J mice
C3HeB/FeJ (original background) F1 mice from Hspy/?9C57BL/6J cross
Wild-type Hush puppy heterozygote Wild-type Hush puppy heterozygote
Left Right Left Right Left Right Left Right
Pinna shape 0% (0/30) 0% (0/30) 73.9% (17/23) 65.2% (15/23) 0% (0/36) 0% (0/36) 6.5% (2/31)
a 6.5% (2/31)
a
Malleus 0% (0/11) 0% (0/11) 0% (0/13) 0% (0/12) 0% (0/36) 0% (0/36) 0% (0/30) 0% (0/31)
Incus 0% (0/36) 0% (0/37) 21.4% (6/29) 14.8% (4/28) 0% (0/36) 0% (0/35) 0% (0/31) 0% (0/29)
Stapes 0% (0/34) 0% (0/37) 96.4% (27/28) 100% (27/27) 0% (0/36) 0% (0/35) 0% (0/31) 3.6%
b (1/28)
Results shown are the percentage of animals with abnormalities, with the number of animals with the defect and number examined in
parentheses. Preyer reﬂex results are not shown; abnormal pinnae often do not ﬂick back when exposed to a click, so the test is not conclusive in
these animals. No defects were found in wild-type animals on either background. On the C3HeB/FeJ background, a single heterozygote animal
was found to have a unilateral stapes defect, but all other heterozygotes had bilateral stapes malformations
a,b The single stapes defect observed in the F1 mice was found in an animal with an ipsilateral pinna defect
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123of activating its signalling pathways: (1) the mutation may
prevent interaction with FGF1, (2) once stimulated, the
mutated receptor may be unable to dimerise and auto-
phosphorylate, and (3) the mutated receptor may be unable
to phosphorylate its target proteins. Due to the location of
the mutation in the tyrosine kinase domain, it is most likely
that either or both of the last two hypotheses account for
the phenotype.
Tyrosine kinases have 11 conserved domains in their
catalytic region, with the greatest degree of conservation
occurring in subdomains VI-IX (Hanks et al. 1988). The
hush puppy mutation in Fgfr1 occurs in the middle of
subdomain IX, conserved in the majority of tyrosine kinase
receptors, including all four isoforms of the Fgfr family,
and for the Fgfr1 isoform it is conserved from zebraﬁsh to
human. In the hush puppy mutant, a tryptophan residue (a
hydrophobic amino acid) located at the end of an alpha
helix (Mohammadi et al. 1996) is replaced by an arginine, a
smaller hydrophilic residue, and is likely to cause disrup-
tion to the secondary structure of this region. Such a model
had been proposed previously for a tyrosine kinase recep-
tor, the insulin receptor, with a similar mutation. The
Fig. 6 Examples of stapes from
the backcross mice, all
heterozygotes for the Fgfr1
Hspy
mutation. a The most modiﬁed
stapes. Both crura appear
relatively normal (score 1).
b Stapes with thinner than
normal posterior crus (score 2).
c Posterior crus is quite thin in
the middle and may be lacking
bone in the centre (score 3).
d Posterior crus lacks bone in
the middle but tissue is still
present forming a very thin link
(score 4). e Posterior crus is
missing but the stapedial muscle
attachment is present at the top
right (score 5). f Posterior crus
is missing, including the
stapedial muscle attachment but
anterior crus appears normal
(score 6). g Posterior crus
completely missing. Anterior
crus is affected and appears thin
and often more widely splayed
than normal (score 7). h Stapes
is bony through area between
crura. The stapedial artery did
not pass through the stapes
(score 8). This feature was
rarely seen (n = 4 ears), and as
it appeared to be qualitatively
different to the other stapes
defects, it was not included in
subsequent analyses. i Diagram
to illustrate the backcross used
to map the modiﬁer
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123tryptophan residue in the same location in subdomain IX in
the insulin receptor (W1227, Supplementary Fig. 10;
originally referred to as W1200S) was found to be mutated
to serine in a heterozygous female patient with non-insulin-
dependent diabetes mellitus, polycystic ovarian disease,
and acanthosis nigricans (Grigorescu et al. 1986; Moller
and Flier 1988). Insulin receptors with the W1227S
mutation were noted to have a 70% impairment of receptor
autophosphorylation when stimulated and were unable to
catalyse tyrosyl phosphorylation of substrate proteins
(Grigorescu et al. 1986; Moller et al. 1990). It was pro-
posed that the mutation may destabilize the hydrophobic
packing of the C-terminal lobe due to the inclusion of the
hydrophilic substitute residue, in turn affecting the tyrosine
kinase function (Hubbard et al. 1994). As both the insulin
receptor and Fgfr1 mutations have similar hydrophilic
substitutions at the same location, this destabilisation effect
may also occur in Fgfr1 in the hush puppy mutant. In
another example, dominantly inherited CATSHL syndrome
(camptodactyly, tall stature, and hearing loss) is associated
with a histidine-to-arginine missense mutation in the
Fig. 7 Genome scans using the
sum of the stapes defect scores
from both left and right ears.
a Polymorphic microsatellite
markers (Table 2) were used on
the DNA of animals that had a
combined left and right score of
2 or 3. These are therefore the
most modiﬁed mice from the
backcross (n = 39 animals).
b Polymorphic microsatellite
markers (Table 2) were used on
the DNA of animals that had a
combined left and right score of
10 or more. These are therefore
the most abnormal (least
modiﬁed) mice from the
backcross (n = 36 animals).
Mice with a solid bony stapes
(Fig. 6H, score 8 on either side;
n = 4) were not included in the
genome scan
Fig. 8 The distribution of the sum of the stapes scores for mice
carrying distal chromosome 7 C57BL/6J DNA (marker D7Mit259)
from their father (violet) and for mice carrying distal chromosome 7
C57BL/6J DNA from their mother (maroon). There is a noticeable
bias toward the more modiﬁed end (scores 2–4) for those mice from a
heterozygote father (Shapiro-Wilks test score for mice from a
heterozygote father: 6.85 9 10
-7; score for mice from a heterozygote
mother: 0.0501)
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123tyrosine kinase domain of FGFR3, although no defects of
the middle ear were detected in affected individuals
(Toydemir et al. 2006).
Thehushpuppymutationleadstodominantinheritanceof
pinna and ossicle malformations, skull anomalies, reduced
rowsofcochlearhaircells,andraisedthresholdsforauditory
responses in heterozygous animals (Pau et al. 2005). Previ-
ous reports of other Fgfr1 mutations have not mentioned
dominant inheritance of any of these features (Deng et al.
1994; Yamaguchi et al. 1994), although other dominant
effects such as a low penetrance of posterior vertebral
transformations in heterozygotes for the Y766F mutation
have been reported (Partanen et al. 1998). Pinna and ossicle
defects were reported inmice homozygous forhypomorphic
mutations that reduced Fgfr1 levels to 10–20% (Partanen
et al. 1998), suggesting that the developing embryo is sen-
sitivetoreceptorlevel.Thehushpuppymutationmayhavea
dominant effect by reducing in some way wild-type Fgfr1
protein to less than the predicted 50% of normal levels in
heterozygotes, or the mutant protein may interact with wild-
typeproteininawaythatreducesitsactivity.Forexample,if
amutantreceptordimerisedwithawild-typereceptor,itmay
inhibit activity of the wild-type Fgfr1 partner, reducing
effective activity to the predicted 25% of dimers containing
only wild-type receptor. Alternatively, mutant protein may
inﬂuence the kinetics of the receptor and/or dimer. Other
mutationsinhumanFGFR1 havepreviouslybeen suggested
toact ina dominantnegativemannerinKallmann syndrome
(Dode et al. 2003; Pitteloud et al. 2006).
The pinna and the middle ear ossicles are both derived
from the same embryological origins, the pharyngeal arches
(PA). The pinna develops from several hillocks that arise at
the dorsal base of PA1 and PA2. The caudal region of PA1
gives rise to the malleus and the incus, as well as the man-
dible, while the stapes is derived from PA2 (for review see
Mallo 1998). Mutants expressing 10–20% of normal Fgfr1
levels have been showntohave greatly reduced pinna size at
birth (Partanen et al. 1998; Trokovic et al. 2003), coupled
withossicledefectsofvaryingseverity,includingabsenceof
most ossicles (Trokovic et al. 2003). The Fgfr1 hypomorph
with20%expressionshowedareductioninsizeofPA2from
E9.5duetoafailureofmigrationofneuralcrestcellsintothe
area (Trokovic et al. 2003). It was proposed that Fgfr1 is
involved in patterning of the pharyngeal region and plays a
permissive role in the migration of neural crest cells into
PA2.
A study by Hoch and Soriano (2006) also found defects
in PA2 development related to Fgfr1 signalling. One of the
proteins that Fgfr1 phosphorylates is ﬁbroblast growth
factor receptor substrate 2 (FRS2a and -b) (Kouhara et al.
1997). FRS2 activates the Ras/MAP kinase pathway via
two routes: (1) recruiting Grb2/Sos complexes, which
activate the pathway (Hadari et al. 1998; Kouhara et al.
1997), and (2) binding the protein tyrosine phosphatase
Shp2, which in turn activates Grb2 (Hadari et al. 1998,
2001). Embryos with Fgfr1 that lacks the binding site for
FRS2a die during late embryogenesis, with defects in
neural tube closure and development of the tail bud (Hoch
and Soriano 2006). It was also found that there were
defects in the development of the PAs such that PA2 was
hypoplastic by E10.5 due to a large reduction in prolifer-
ation of the mesenchymal cells. The derivatives of PA2
were selectively affected in mutant embryos, with E15.5
embryos having missing or hypoplastic stapes. Combining
the evidence described here, it would seem plausible that
patterning defects in PA2 due to a reduction in Fgfr1 sig-
nalling cause the hush puppy heterozygous phenotype. The
stapes defect could be the result of insufﬁcient FRS2a
activation due to a decrease in functional Fgfr1.
We propose that the missense mutation W691R in the
Fgfr1 gene is responsible for the phenotypic defects in
hush puppy mice for several reasons. Firstly, the gene is
located in the nonrecombinant region of chromosome 8
(Pau et al. 2005), and the most penetrant feature (the stapes
crura malformation) always segregates with the mutation.
Secondly, Fgfr1 is known to be expressed widely in the
craniofacial region, including structures affected by the
mutation (Bachler and Neubu ¨ser 2001; Rice et al. 2003).
Thirdly, the affected residue is highly conserved and is
located in an important functional region, the kinase
domain. Fourthly, we have shown that the mutation affects
two key roles of the receptor, its ability to activate the IP3
pathway and the RAS/MAP kinase pathway. Finally, the
hush puppy mutant has several features in common with
known hypomorphic mutations of Fgfr1, such as lethality
of the homozygotes at around the time of gastrulation,
malformation of the stapes, and pinna defects (Hoch and
Soriano 2006; Trokovic et al. 2003).
We found some variation in the phenotype of hush
puppy mutants, including asymmetric defects in individual
mice. Variability in the phenotype has been reported for
other mutations of Fgfr1, and mixed genetic background is
known to be a complicating factor inﬂuencing penetrance
of the abnormalities (Hoch and Soriano 2006). The hush
puppy mutation originated and is maintained on an inbred
C3HeB/FeJ genetic background, indicating that the vari-
ability in phenotype most likely is inﬂuenced by stochastic
events in addition to genetic background effects.
Modiﬁer genes have been found for numerous patholog-
ical mutations, including those responsible for deafness,and
range from genes affecting transcription or translation, such
asNxf1,anRNAexportproteinthatcancompensateforlarge
intronic IAP insertions (Floyd et al. 2003), to genes directly
involved in the mechanisms affected by the mutation, in
either the same pathway or possibly an alternative one such
asthemodiﬁeroftubbyhearing(moth1),whichisanalleleof
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123the neuron-speciﬁc gene Mtap1a (Ikeda et al. 2002). In the
case of hush puppy, the mutation appears to disable the
phosphorylationabilityoftheprotein,soamodiﬁermightbe
expected to compensate for that inability. The stapes and
pinna genome scans indicate that a potential modiﬁer
(Mhspy) of these aspects of the hush puppy phenotype is
located at the distal end of chromosome 7. Interestingly, this
region includes Fgfr2, another tyrosine kinase receptor
knowntobeexpressedintheoticepitheliuminasimilarway
to Fgfr1 (Pirvola et al. 2004). The four Fgf receptors have a
conservedstructurewithvaryingdegreesofhomologyinthe
different domains [from 21–38% in the amino-terminal
domain to 74–92% in the tyrosine kinase domain (Partanen
et al. 1991)] and can bind multiple FGF ligands (Givol and
Yayon 1992; Zhang et al. 2006). Like Fgfr1, mutations in
Fgfr2 can lead to Pfeiffer syndrome (Schell et al. 1995). In
the process of lens differentiation, Fgfr1, Fgfr2, and Fgfr3
are functionally redundant (Zhao et al. 2006), and in other
situations,mutationsinFgfr2allowFgfr2tofulﬁlltheroleof
Fgfr1 where it would otherwise be incapable; for example,
Fgfr2 is not normally capable of Fgf1 translocation, but two
amino acid changes in the C-terminus enable the protein to
dothat(Sørensenetal.2006).OthermutationsinFgfr2have
been shown to increase signalling, particularly through
affecting FRS (Ahmed et al. 2008; Hatch et al. 2006; Moffa
and Ethier 2007), so Fgfr2 would be a prime candidate in a
search for this modiﬁer. Other genes encoding components
of FGF signalling pathways are located on distal chromo-
some 7 and are also candidates for Mhspy, including Fgf3,
Fgf4,andFgf15.Dusp8ondistalchromosome7mayalsobe
a candidate, because a related gene, Dusp6, has been shown
to regulate Fgf signalling (Li et al. 2007). Comparisons of
coding and splice site sequence in these ﬁve potential mod-
iﬁer genes between the C57BL/6J reference sequence and
C3H/HeJ (a related C3H line) show no obvious differences
that might explain the modiﬁer effect observed. However,
there are several SNPs that are either synonymous or pres-
ent in the UTRs of Fgf3, Fgf4, Fgf15, and Dusp8, and it
is possible that these could play a role. We found sugges-
tive evidence that Mhspy may be subject to imprinting,
although none of these candidate genes has been reported
to be imprinted. We compared the reported C57BL/6J
and C3H/HeJ sequence for exons, splice sites, and UTRs of
genes within or close to the known imprinted clusters on
distal chromosome 7 (H19, Igf2, Ins2 in one cluster and
Osbp15, Nap1l4, Phlda2, Tssc5/Slc22a18, Cdkn1c, Kcnq1,
Kcnq1ot1, Tssc4, Cd81, and Ascl2 in the other cluster, plus
Cars which is close to imprinted regions). Cars showed one
nonsynonymous SNP at position 150745083 (rs13459436),
changing a serine to glycine, but no other reliable sequence
changes were observed.
Mutations in Fgfr1 have been identiﬁed in several human
syndromes. Pfeiffer syndrome is caused by a variety of
mutations in Fgfr1, causing a range of symptoms such as
premature skull fusion, underdevelopment of the midface,
defectsofthehandsandfeet,anddeafnessin*50%ofcases.
However, it is unlikely that the hush puppy mutation is a
model of Pfeiffer syndrome because the mutation in this
human disease leads to upregulation of receptor function,
whereasthehushpuppymutationinFgfr1causesaninactive
form of the receptor. Kallmann syndrome can be caused by
loss-of-function mutationsinFGFR1(Albuissonetal.2005;
Dodeetal.2003;Pitteloudetal.2005;Satoetal.2004).This
syndrome is characterised by hypogonadism and anosmia,
but unilateral hearing loss has been reported in one indi-
vidual (Dode et al. 2003). Mice doubly heterozygous for the
hush puppy mutation and a nonsense mutation in Chd7
(another gene associated with Kallmannsyndrome)show no
sign of the Kallmann phenotype, so it would seem unlikely
thathushpuppymicecouldbeananimalmodelforKallmann
syndrome (Bergman et al. 2010). A disease recently attrib-
uted to mutations in Fgfr1 is osteoglophonic dysplasia,
whichischaracterisedbyshortstature,craniosynostosis,and
bone demineralisation. This condition is caused by activat-
ing mutations of Fgfr1 in speciﬁc extracellular and trans-
membrane regions of the gene (Supplementary Fig. 11)
(White et al. 2005). Although skull defects have been noted
in hush puppy heterozygote animals, the hush puppy muta-
tion is unlikely to be a model for this disorder due to the
location of the mutation. However, as these examples show,
it is only recently that human conditions are being attributed
to mutations in FGFR1; therefore, the hush puppy Fgfr1
mutant may yet be found to represent a human disorder
(Supplementary Fig. 11) (Wilkie 2008).
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